New identified risk of hepatotoxicity (including hepatic failure) in patients treated with Imbruvica®

A Dear Healthcare Professional Letter has been issued by Johnson & Johnson International (Singapore) Pte Ltd to inform healthcare professionals about a new identified risk of hepatotoxicity, including hepatic failure, which has been reported in patients treated with Imbruvica®. This causal association is based on a recent cumulative review of data from clinical trials, post-marketing cases and literature by Johnson & Johnson and the Imbruvica® package insert will be updated accordingly. Healthcare professionals are advised to discuss with patients the risks associated with the use of Imbruvica®, including hepatoxicity and hepatic failure. It is recommended to assess liver function before initiating treatment with Imbruvica® and monitor patients periodically for changes in liver function parameters during treatment. Please refer to the letter for details.

 

Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

30 Sep 2024

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.